ArticleOpen forum infectious diseases2026
The Impact of Directly Observed Therapy on Successful Tuberculosis Treatment: A Statistical Analysis of National Notifications Data.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Directly Observed Therapy (DOT) is a recommended modality for tuberculosis (TB) treatment, yet is underutilized in many settings. Although DOT has been evaluated in clinical trials, less is known about its effectiveness in routine programs. We estimated the contribution of DOT to TB treatment success in Brazil. Methods: Using data from Brazil's National Disease Notification System for 2015-2018, we fit regression models estimating the relationship between DOT coverage and individual treatment success, leveraging municipality-level variation in DOT usage to avoid confounding due to nonrandom DOT receipt at the individual level. Models were adjusted for demographic and clinical covariates, using generalized estimating equations to account for correlation of outcomes within municipalities. Fitted models were used to project the impact of expanded DOT coverage, with robustness tested using alternative specifications. Results: The study included 278 007 individuals from 4783 municipalities. Average DOT coverage was 45.3%, with significant geographic variability. Treatment success was 86.9% with DOT and 73.2% without DOT. DOT coverage was associated with a 1.46 (95% confidence interval: 1.38, 1.55) odds ratio (OR) of treatment success. ORs ranged from 1.11 to 2.52 under alternative specifications, consistently indicating a positive impact. Scenario analyses indicated that reducing DOT nonutilization in each municipality by 50% would reduce the proportion of unsuccessful treatment outcomes by 7.1% (6.1, 8.2), equivalent to an average 5.5 (4.7, 6.3) percentage point increase in success probability for individuals newly receiving DOT. Conclusions: In this routine programmatic setting, higher DOT utilization was associated with better treatment outcomes, underscoring the importance of adherence-supported interventions for TB care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.